Actually, yes,but only with GLP-1s like retatrutide. When you have inaccurate dosing with GLP-1s you have side effects like nausea, vomiting, etc.
But compounds like BPC-157 have never had an established LD1 for toxicity so obviously we're not going to see patients coming to the ED based off of that.
But we do have problems when it comes to standardized dosing and characterizing responses.